A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)

NCT06688240 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
120
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Servier (Tianjin) Pharmaceutical Co. LTD.

Collaborators